Natera, Inc. (NASDAQ:NTRA) Stock Holdings Increased by Calamos Advisors LLC

Calamos Advisors LLC boosted its stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 29.0% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 29,637 shares of the medical research company's stock after purchasing an additional 6,667 shares during the period. Calamos Advisors LLC's holdings in Natera were worth $4,191,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. LRI Investments LLC purchased a new position in shares of Natera during the 4th quarter valued at $29,000. Rakuten Securities Inc. boosted its position in Natera by 117.8% during the first quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock valued at $31,000 after purchasing an additional 119 shares during the last quarter. ORG Partners LLC acquired a new stake in Natera during the first quarter valued at $32,000. EverSource Wealth Advisors LLC grew its stake in Natera by 372.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock valued at $52,000 after purchasing an additional 261 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC increased its position in Natera by 1,328.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company's stock worth $57,000 after purchasing an additional 332 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.

Natera Stock Performance

Shares of NASDAQ:NTRA opened at $161.50 on Friday. The stock's 50-day moving average is $160.34 and its 200-day moving average is $158.44. The company has a market cap of $22.05 billion, a P/E ratio of -109.86 and a beta of 1.73. Natera, Inc. has a 52-week low of $92.14 and a 52-week high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last released its earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.59) by $0.09. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. The firm had revenue of $501.83 million for the quarter, compared to analyst estimates of $446.68 million. During the same quarter last year, the firm posted ($0.56) EPS. The company's revenue was up 36.5% on a year-over-year basis. As a group, equities analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Wall Street Zen lowered Natera from a "hold" rating to a "sell" rating in a report on Saturday, May 17th. UBS Group raised their price objective on shares of Natera from $211.00 to $218.00 and gave the company a "buy" rating in a research report on Friday, May 9th. Royal Bank Of Canada initiated coverage on shares of Natera in a research note on Thursday, March 13th. They issued an "outperform" rating and a $251.00 target price for the company. Piper Sandler increased their price target on shares of Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a research note on Thursday, May 15th. Finally, Barclays raised their price target on shares of Natera from $160.00 to $190.00 and gave the company an "overweight" rating in a report on Friday, May 9th. One research analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $184.63.

Insider Activity at Natera

In other Natera news, insider Solomon Moshkevich sold 3,000 shares of the company's stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $166.77, for a total value of $500,310.00. Following the completion of the transaction, the insider owned 130,205 shares of the company's stock, valued at $21,714,287.85. This represents a 2.25% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Michael Burkes Brophy sold 2,018 shares of the firm's stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $152.18, for a total value of $307,099.24. Following the completion of the sale, the chief financial officer owned 73,539 shares of the company's stock, valued at $11,191,165.02. This represents a 2.67% decrease in their position. The disclosure for this sale can be found here. Insiders sold 53,272 shares of company stock valued at $8,345,368 in the last quarter. Company insiders own 7.60% of the company's stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.